Many use mice for contemporary cardiovascular research, as we should, given the power of the genetic and other tools developed to permit rigorous mechanistic experimentation in this species. We must remain mindful, nonetheless, of the reasons why the results of mouse experiments may not extrapolate readily to human disease. Large gaps separate our mouse experiments and clinical conditions. The differences arise from the genetic homogeneity of inbred mouse strains used in experimentation, the restricted exposure of mice to many microbes and a more monotonous microbiome in mice than in free-living rodents and humans, lack of comorbidities, focus on youthful mice and exaggerated experimental conditions contrived to speed up studies, and the lack of congruence between many experimental “models” and human cardiovascular conditions. We must and should continue to mine studies on mice for the incredibly valuable mechanistic insight they provide. Yet, we as a community could consider more carefully some of the barriers to glib extrapolation of the results of experiments in mice to human disease.

These experimental results in mice suggest that X is a promising novel target for the treatment of human cardiovascular disease

(A paraphrase of the concluding sentence of many contemporary cardiovascular research papers).

Most use mice. We must use mice for much contemporary cardiovascular experimentation. Yet, we must not succumb to group think about the ready translatability of our experimental results to the results obtained in the clinic. Although many millennia of evolution separate them from humans,1 mice provide incredibly valuable tools for biomedical investigation. In particular, the availability of inbred strains and the development of ever more powerful techniques for sophisticated genetic manipulation allow reductionist experiments of increasing complexity, sophistication, and rigor. Nonetheless, the primacy of mice as experimental animals for cardiovascular research during the past decades may have fostered a tendency to minimize some of the limitations of modified mice as models for human diseases. This article highlights some of the issues to which we as a community might pay more heed to in interpreting and extrapolating the results of our mouse experiments to humans. I do not denigrate the use of these powerful approaches to experimental work. Rather, this article aims to raise some of the issues that require consideration and rigorous thinking about the relationship of our laboratory approaches with clinical cardiovascular conditions. I consider serially several such potential limitations (Figure).

Congenic Strains—An Enabling Strength, but also a Potential Weakness

We possess a repertoire of more than 100 exceedingly well-characterized congenic strains of mice. Generations of brother/sister mating in this species lead to construction of lines of mice with virtual genetic identity. This tactic provides a homogeneous preparation that reduces the variability in our experiments and renders them more readily reproducible. Yet, these very virtues represent a potential barrier to extrapolation of results to human populations. As opposed to our popular mouse strains used in cardiovascular investigation, taboo, custom, social mores, and strong biological drivers constrain consanguinity in human societies. In contrast to the genetic uniformity of inbred mice, our patients present a varied genetic palette. We know from quantitative trait locus mapping and other studies in mice that modifier genes can markedly influence the pathophysiological consequences of various genetic variants.2–4 We have also learned that studying a specified genetic alteration on different genetic backgrounds can markedly influence the phenotypic expression. Thus, while offering an enormous advantage for experimental rigor, the use of congenic strains presents, prima facie, an enormous gap between the laboratory and the clinic. Genetic variation in human populations has important health implications. For example, polymorphisms in the major histocompatibility complex likely permit human populations to survive various epidemics, as some individuals will mount an immune response to a given pathogen better than others. Thus, genetic variability likely contributes to the survival of the human species. Experiments in congenic mice eliminate this biologically important attribute of human populations.
Figure. Mice are mice, not models. This photograph shows mice that guard the threshold to Otoyo Shrine, one of the treasures on the Philosophers’ path (tetsugaku no michi) in Kyoto, Japan (A). Appropriately, this shrine celebrates health, longevity, and mating (matrimony for us, humans). The selection of mice as guardians of this shrine has nothing to do with the premise of this commentary. Rather, this statuary reflects an ancient Japanese myth that recounts how a mouse saved a suitor from dire distress. One of the guardian mice carries a scroll (high power view, B), which we might regard as a manuscript for submission to Circulation Research or a grant application. The other mouse (high power view, C) bears a sake cup that he might fill locally, as the shrine usually houses ample offerings of large tubs of sake (Online Figure I). Perhaps the sake-bearing mouse aims to provide solace to his aggrieved scroll-bearing brother when he receives his decision letter from the journal editors or the summary statement from study section. For the cardiovascular investigator, the positioning of these statues of mice on pedestals has appeal, as this species has proven pivotal in moving cardiovascular research forward. It is the interpretation and overly simplistic extrapolations of results to the clinic of which we must remain mindful. To paraphrase Shakespeare’s Cassius: “The fault, dear colleagues, is not in the mice, but in our selves” (Julius Caesar, Act I, Scene II, Lines 140–141). Photographs in panels B and C are taken from http://www.GoJapanGo.com.
The Hygiene Hypothesis and the Microbiome as a Barrier to Translatability of Laboratory Experiments in Mice to Those in Humans

Our shiny modern animal facilities tout a specific pathogen-free environment. We carefully protect our experimental mice from the onslaught of potentially pathogenic microorganisms that they would encounter in the field. In contrast to our contrived laboratory environment, human populations have constant exposure to varied pathogenic and commensal microbial organisms. Moreover, we have increasing recognition that the intestinal microbiome can critically influence the expression of various diseases including those that affect the cardiovascular system, in both humans and mice. Our laboratory mice engage in coprophagia, a behavior that favors the perpetuation of a particular microbial environment in carefully caged animals. In contrast, rodents in the field, more like human populations, undergo varied and continuous exposure to microorganisms that would yield much greater heterogeneity in the microbiome that would educate immune responses more intensely.

These considerations reflect a variant of the “hygiene hypothesis” that microbial challenges to the immune system in more sanitary environments affect the development of the immunity. Indeed, wild rats and wild mice exhibit higher IgG and IgE concentrations in serum than rodents in the laboratory. The immune system of wild-caught rats contrasts considerably with that of laboratory animals in relation to T-cell characteristics as well. Some have invoked the hygiene hypothesis to explain increases in allergic diseases in postindustrial societies. From our experimental perspective, we must remain mindful that the immune system of our favorite laboratory mice may vary considerably from that of field mice and of human populations exposed to a broader environment of microbes both pathogenic and commensal. The lack of constant challenge by a diversity of microorganisms and a more monotonous microbiome distort the immune response in our laboratory mice. Moreover, the continuous exposure to a variety of microorganisms educates human adaptive immunity, providing a menu of memory responses that may vary substantially from primary responses. De novo responses evoked in mice with a more restricted experience with microorganisms may yield a different picture from memory responses in humans.

Mice Have a More Categorical Immune System Than Humans

Another challenge to the ready translatability of experiments in the immune system in mice versus the immune system in humans relates to the apparently less strict demarcation between functional subtypes of both innate and adaptive immune cells in humans than the subtypes in mice. For example, an enormous literature has focused on Th1 versus Th2, regulatory T-cell (Treg) functions, and differences between B1 and B2 lymphocytes in experimental preparations. In the realm of innate immunity, the study of M1 versus M2 macrophages has become a common refrain. Yet, considerable evidence suggests that the strict categorization of these functional subsets of both adaptive and innate immune cells in humans has more diffuse borders and perhaps greater instability than that is evident in the mouse. Immunologic researchers have called attention to the differences in functional markers and stability of Tregs in mice versus humans. Moreover, the markers commonly used for phenotyping macrophages in mice render less clear results in humans. Interpretation of the results of manipulations of the mouse immune system for human disease should take these disparities into account more frequently.

Are Our “Models” Really Such?

We often engage in laboratory perturbations in mice with various genetic modifications to delineate the roles of specific mediators in human disease. Such an approach offers enormous value. Yet, our manipulations, while convenient and often reproducible, may stray substantially from replicating the human situation. For example, generations of studies of arterial injury in the quest of new therapies for restenosis after clinical arterial intervention used previously normal animals. There is little reason to expect that the response to arterial injury in a previously normal vessel would faithfully model clinical percutaneous arterial interventions performed on atherosclerotic arteries. Many rodent arterial injury experiments use withdrawal of an overexpanded balloon, deployment of an overexpanded stent, or abrasion produced by repeated passage of a wire as the model injury. Yet none of these manipulations mimics clinical percutaneous arterial intervention. These differences, to which we called attention in 1992, could contribute to the huge disparity between interventions that proved effective in animal experiments but were disappointing in the clinic.

In the realm of complications of atherosclerosis, many articles on mouse experiments refer to features of plaque stability or instability. Experimentally induced plaques in mice seldom disrupt and cause thrombosis, rendering the use of these terms highly suspect. Many studies on mice have addressed the pathogenesis of abdominal aortic aneurysms. At least 3 types of manipulations can induce abdominal aortic abnormalities in mice: the combination of hyperlipidemia and angiotensin II infusion, perfusion with elastase, and peri-aortic exposure to calcium chloride. None of these manipulations faithfully replicate the human condition. The lesions induced by angiotensin II infusion in hyperlipidemic mice, widely used by our own and many other groups, likely arise from transmural penetrating ulcers of the aorta with periarterial hemorrhage, thrombosis, and organization. These lesions do not localize to the infrarenal region, a characteristic of human abdominal aortic aneurysms. Such examples illustrate how arterial lesions produced in mice do not undergo complications that lead to clinically important manifestations of the disease in humans.

Likewise, in studies of myocardial biology, we perform transverse aortic constriction in mice that often have previously normal hearts in an attempt to model the disease of human hearts that often have chronic rather than acute pressure overload that yields an abnormal heart before experiencing critical outflow obstruction. Similarly, our common ischemia/reperfusion preparations in the mouse myocardium start with a normal vasculature and myocardium rather than one diffusely affected by atherosclerosis and previous ischemic insults.
Is it thus surprising that few if any of the multitudinous manipulations that have improved the outcome of experimental ischemia/reperfusion injury in mice and other animals have borne fruit in the clinic?

**Mouse Experiments Usually Fail to Account for Comorbidities Common in Our Human Patients**

The foregoing section highlighted distinctions between the normal substrate for intervention, both vascular and myocardial, in mice versus the human situation usually affected by chronic diseases of those organs. Beyond the cardiovascular system, our patients usually present with comorbidities that interface inextricably with their cardiovascular disease. Common concomitant conditions include renal dysfunction, diabetes mellitus, obesity, tobacco abuse, periodontal disease, and pulmonary disease. These comorbidities inevitably influence the expression of cardiovascular disease. We appreciate increasingly the crosstalk between acute and chronic inflammatory activation remote to the myocardium or atheroma and echoes within the cardiovascular system.\textsuperscript{14,15,16} Our well-defined and reproducible mouse experiments again fail to replicate the complexity of clinical cardiovascular disease whose course often depends on concomitant comorbidities.

**The Time Scales of Laboratory Investigations and Human Disease Vary Considerably (Funding Cycle versus Life Cycle)**

Laboratories depend on funding cycles of a few years. Graduate students and postdoctoral fellows in common with principal investigators need to finish projects in a timely fashion to permit publications that allow them to advance to the next echelon of their professional careers or obtain the next time-limited cycle of grant funding to support their research. These constraints cause us to eschew the long-term experiment in favor of short-term manipulations that can generate data rapidly and meet the short-term goals imposed on us by professional ladders and funding organizations.

Hippocrates famously stated, “The art is long, life is short… experiment difficult,...” He was doubtlessly correct for his era, and his assessment of the difficulty of experiment endures. Yet, the sage had no conception that by making inroads in communicable diseases and other advances, both societal and medical, the human lifespan would become a lot longer in the 21st century than in classical antiquity. Cardiology patients continue to shift toward an accumulation of the aged. As our experiments remain short, we adopt models of disease that do not reflect aging of the cardiovascular system.

Atherosclerotic mice commonly used in the laboratory typically have degrees of genetically or dietarily determined hyperlipidemia that caricature rather than mimic the human conditions. Such acceleration produces atherosclerotic lesions in mice in weeks not in years. Yet, we blithely expect the lesions so produced to represent the ravages of a disease that plays out over decades in humans. In our haste to complete the next article, to finish the thesis, and to compete for grant funding, we tend to sweep under the rug the enormous differences in time scale and the intensity of interventions that separate clinical and experimental disease in our cardiovascular laboratories.

**Human Studies Have Limitations Too**

The foregoing cautionary statements regarding studies on mice raise some similar limitations inherent in many clinical trials. As the interpretation of animal experiments requires caution, so too does the design and extrapolation to broader practice of clinical investigations. For example, although our human populations included in clinical trials lack the genetic homogeneity of inbred strains, we must strive to be more inclusive of individuals from different geographic locations and ethnicities when recruiting them for clinical trials. In particular, we must maximize the participation of women, a growing segment of our cardiovascular patient population. Entry criteria for clinical trials often also exclude comorbidities such as advanced renal disease or cancer, conditions commonly encountered in clinical practice. Clinical trials also usually exclude the elderly, another portion of the population on the rise. We span of our experimental studies depends on academic and grant funding cycles. The duration of clinical trials also confronts time limitations because of the haste of the sponsor and the academic investigators alike to conclude a study, albeit for distinct reasons. We often encounter disappointment when extrapolating the results of smaller phase 2 studies, particularly those that use surrogate end points rather than clinical events.

We must bear these limitations in mind when evaluating human studies, as I urge for experimental work above.

**Conclusions and Implications**

These and doubtless other important considerations highlight the challenges of interpreting our investigations conducted in mice. Should we therefore abandon such experiments? That conclusion comprises a reductio ad absurdum. We should and must use mouse experiments to propel our field forward. Nonetheless, we must not neglect the gaps that yawn between these convenient and powerful animal preparations and human disease. Many hundreds of published papers reporting cardiovascular research have conclusions that paraphrase the aforementioned introductory quotation that the results uncover a new target for therapy of human disease. Few of the findings touted in these promissory statements have actually led to new treatments proven to benefit patients. We do a disservice to our trainees and to clinical investigative colleagues to minimize the enormous distance; effort; and expenditure of time, energy, and resources that stand between the glib extrapolations in our research papers; and the reality of clinical translation. Although the rigor, reproducibility, and practicality of mouse experiments provide compelling reason for their continued widespread use in cardiovascular investigation, we could well adopt a bit more caution in our rush to extrapolate results to the clinic.

Facile statements in experimental papers regarding the translatability of the findings unwittingly demean clinical trialists who travel the long, arduous, and perilous road actually required to test hypotheses regarding the efficacy of therapeutic interventions in humans. It takes the basic science
Gaps Between Mouse Experiments and Human Disease

Our laboratory group tries to practice the discipline of using the term “model” cautiously. We favor the stance that animal experiments provide us with a rich opportunity to test defined hypotheses regarding pathophysiologic mechanisms under tightly controlled circumstances. This approach applies not only to mice but also to experiments performed in other species: rats, rabbits, fish, and worms alike. I challenge trainees and colleagues with the assertion that attempts to model a human disease in mice virtually guarantee failure. I prefer the nostalgic term “preparation” as a more humble and perhaps realistic replacement for the word “model.”

Ultimately, cardiovascular science will continue its impressive advance by combining the rigor and control of laboratory experimentation with the much muddier reality of human patients and populations: the delight and challenge we encounter in daily practice. To achieve this end, we must continue to train physician-investigators, to encourage dialogue between laboratory scientists and clinical investigators, and to apply a dose of humility and introspection to the implications of our experimental work for human disease.

Disclosures

None.

References


Keywords: comorbidity ■ hygiene hypothesis ■ mice ■ microbiota ■ research
Murine "Model" Monotheism: An Iconoclast at the Altar of Mouse
Peter Libby

Circ Res. 2015;117:921-925
doi: 10.1161/CIRCRESAHA.115.307523
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/117/11/921

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2015/11/05/CIRCRESAHA.115.307523.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/
Supplementary Figure Legend
A) This photograph shows the offerings of sake at Otoyo Shrine. B) The author and C) Dr. Melissa Hancock visiting the mice of Otoyo Shrine near the end of a morning run on the Philosophers' Path in Kyoto. D) White mice welcoming visitors to Otoyo Shrine.